SynBioBeta Speaker
Tina Boville
Aralez Bio
Co-founder & CEO
Tina Boville is the co-founder and CEO of Aralez Bio, a startup that designs and manufactures noncanonical amino acids for a bio-based future. After earning her Ph.D. in biochemistry from the University of Colorado, Boville co-invented Aralez Bio’s foundational technology while conducting postdoctoral research at Caltech in the lab of Nobel Laureate Prof. Frances Arnold. Recognized as an MIT Technology Review Innovator Under 35, Activate Fellow, and Biotech Founder to Watch, Boville seeks the noncanonical—the different and the innovative—to propel biology where it has not yet dared to go.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Tina
This Year
•
-
Tools & Tech
Engineering Resilient Pharma Supply Chains with Biology
For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.
Get a Ticket
Featuring
Ola Wlodek
Constructive Bio
CEO
Leader in Non-Canonical Amino Acids and genome design
Christina Smolke
Antheia
CEO & Co-Founder
Synthetic-biology pioneer decoupling medicines from fragile supply chains.
Tina Boville
Aralez Bio
Co-founder & CEO
Enzyme engineer expanding peptide chemistry’s noncanonical frontier.
•
-
Tools & Tech
Engineering Resilient Pharma Supply Chains with Biology
For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.
Get a Ticket
Featuring
Ola Wlodek
Constructive Bio
CEO
Leader in Non-Canonical Amino Acids and genome design
Christina Smolke
Antheia
CEO & Co-Founder
Synthetic-biology pioneer decoupling medicines from fragile supply chains.
Tina Boville
Aralez Bio
Co-founder & CEO
Enzyme engineer expanding peptide chemistry’s noncanonical frontier.
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
